ICU Medical (ICUI)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
$167.58+0.78%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
QuarterlyIQ Insights · ICUI
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 3.0% |
| Our one-year growth estimate | diamond | 4.2% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 1.2 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 25 industry peers · Company calendar date is not available
ICUI — officer change
Dated 2026-02-20
The filing pertains to an amendment of the Executive Severance Plan, which is a routine administrative matter.
Why it matters: Raising guidance shows confidence in better operations and cash flow.
Supportive ifAdjusted EBITDA guidance is raised to over $435 million. This shows strong operations.
Worry ifGuidance stays at or below $435 million. This shows possible operational problems.
Why it matters: Hitting this target shows management can improve profits and cash flow.
Supportive ifAdjusted EBITDA meets or exceeds $415 million for the full year 2026.
Worry ifAdjusted EBITDA is under $400 million. This raises worries about how well the company runs.
Why it matters: If revenue stabilizes, it shows recovery after the Q1 drop. This helps management focus on making more money.
Supportive ifQ2 2026 revenue shows no decline year over year, ideally growing above $530 million.
Worry ifQ2 2026 revenue declines year over year worse than -12%.
Why it matters: Revenue growth shows how ICU Medical is bouncing back after selling IV Solutions.
Worry ifQ2 revenue growth is less than or equal to 0% year over year.
Less concerning ifQ2 revenue growth exceeds 5% year over year.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$147 on $10,000 · ±1.5% | How much price usually moves either way. |
| Bad day | $324 loss on $10,000 · 3.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,718 loss on $10,000 · 27.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: If net income is over $73 million, it shows management is working to improve profits.
Supportive ifNet income for 2026 is over $73 million. This supports management's efforts to improve.
Worry ifNet income is below $26 million. This suggests challenges in making profits.
Why it matters: If gross profit is under $206.2 million, it shows problems in making more money. This is a main focus for management.
Worry ifQ2 2026 gross profit reported above $206.2 million.
Less concerning ifQ2 2026 gross profit reported below $206.2 million.
Why it matters: More cash from operations means better financial health. It also shows more efficiency.
Supportive ifCash from operations increases by more than 10% in Q2.
Worry ifCash from operations decreases or grows less than 5% in Q2.
Why it matters: Keeping net income above this level shows good financial health and cost control.
Supportive ifQ3 net income is over $19 million, showing strong financial results.
Worry ifQ3 net income is under $10 million. This suggests possible challenges in operations.
Why it matters: A better gross profit margin shows that products are making more money. This is key for growth.
Supportive ifQ2 2026 gross profit margin reported above 39%.
Worry ifQ2 2026 gross profit margin reported below 39%.
Why it matters: More cash flow from operations shows better financial health. This helps support growth.
Supportive ifCash from operations is over $119.1 million. This shows strong cash generation.
Worry ifCash from operations falls below $119.1 million, suggesting cash flow issues.
Why it matters: If cash from operations exceeds $51 million, it shows management's success in enhancing cash flow. This supports their operational goals.
Supportive ifIn Q2 2026, cash from operations was over $51 million.
Worry ifIn Q2 2026, cash from operations was under $51 million.
Why it matters: Slower cash growth could hurt management's plans for expansion and investment.
Worry ifCash from operations growth falls below 10% year over year.
Less concerning ifCash from operations growth remains above 10% year over year.
Why it matters: If growth is higher, it shows strong demand and good management after selling IV Solutions.
Supportive ifQ3 revenue grew more than 6% from last year. This shows strong performance.
Worry ifQ3 revenue growth is less than 1% from last year. This may mean demand issues.
Why it matters: Higher net income helps ICU Medical succeed. It also builds trust with investors.
Supportive ifQ2 net income grows year over year by more than 10%.
Worry ifQ2 net income declines year over year.
Why it matters: A slowdown in sector growth could impact ICU Medical's performance and outlook.
Worry ifSector revenue growth drops below 8% year over year.
Less concerning ifSector revenue growth remains above 10% year over year.
Why it matters: Higher net income means ICU Medical is managing costs well and making more money.
Supportive ifGAAP net income for Q3 2026 exceeds $19.1 million, the Q2 2026 figure.
Worry ifGAAP net income for Q3 2026 is below $19.1 million.
Why it matters: More cash flow from operations means better financial health. It also shows more efficiency.
Supportive ifNet cash from operating activities for Q3 2026 is over $119.1 million.
Worry ifNet cash from operations for Q3 2026 is below $119.1 million.
Why it matters: A steady or rising gross margin means ICU Medical is controlling costs well.
Supportive ifGAAP gross margin for Q3 2026 remains above 43%.
Worry ifGAAP gross margin for Q3 2026 falls below 43%.
Why it matters: Changes in sector growth can affect ICU Medical's revenue. This can change its market position.
Watch forSector revenue growth is speeding up again, reaching over 9%.
Also watch forSector revenue growth slows below 5%.